At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CPRX Catalyst Pharmaceuticals
Market Closed 05-17 16:00:00 EDT
16.49
+0.09
+0.55%
盘后16.77
+0.28+1.69%
19:58 EDT
High16.85
Low16.32
Vol1.11M
Open16.55
D1 Closing16.40
Amplitude3.26%
Mkt Cap1.95B
Tradable Cap1.68B
Total Shares118.12M
T/O18.35M
T/O Rate1.09%
Tradable Shares101.89M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.